对喘的个性化治疗方法
Ioana Agache1, Ian M Adcock2, Federico Baraldi3
1Transylvania University, Brasov, Romania.
The Journal of allergy and clinical immunology
|April 9, 2025
概括
由于个体宿主和环境因素,喘管理是复杂的. 本综述指导临床医生通过整合基因组学,暴露组和过敏性数据来定制治疗,以实现个性化的喘药物.
科学领域:
- 肺病学和过敏症的研究
- 遗传学和基因组学 遗传学和基因组学
- 环境健康 环境健康
背景情况:
- 喘在临床表现,进展和治疗反应方面表现出显著的异质性.
- 宿主易感性和环境暴露显著影响喘的多样性特征.
- 由环境暴露改变的基因组,表观基因组,转录基因组,蛋白质基因组和代谢基因组因素有助于这种异质性.
研究的目的:
- 通过个性化医疗模式指导临床医生在喘管理决策中.
- 审查影响喘发展和进展的关键因素.
- 为精准医学在喘护理中提供综合目标.
主要方法:
- 对喘的生物学特征的审查,包括基因组学,暴露组和过敏反应.
- 针对性生物药物和过敏原免疫治疗的讨论.
- 检查多变量集群分析和适应性试验设计,以实现个性化治疗策略.
主要成果:
- 确定导致喘异质性的关键因素.
- 探索治疗目标,如上皮,粘液生产,气道光滑肌肉和小气道.
- 评估先进的分析方法,如集群分析和适应性试验,以告知治疗.
结论:
- 个性化医疗方法对于管理复杂喘至关重要.
- 整合多omics数据,环境暴露和过敏度概况可以优化喘治疗.
- 多变量分析和适应性试验设计对表征疾病异质性和指导精确治疗具有前景.
相关概念视频
Asthma-I: Introduction
2.6K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
2.6K
Asthma-IV: Diagnostic and Management
2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
Asthma-IV: Nursing Management
2.9K
The nursing management of asthma is a comprehensive approach that relies heavily on the expertise and dedication of healthcare professionals. It involves thorough assessment, accurate diagnosis, strategic planning, effective implementation, and diligent evaluation. By meticulously following this step-by-step process, healthcare professionals play a crucial role in providing the best possible care and treatment for patients with asthma, enhancing their overall health and well-being.
First, in...
First, in...
2.9K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
182
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
182
Asthma: Pathogenesis and Management
259
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
259
Antiasthma Drugs: Leukotriene Modifiers
172
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
172


